Last update 12 Dec 2024

Pemetrexed Disodium Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MTA, Multitargeted antifolate, PEMETREXED
+ [31]
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors), GART inhibitors(GAR transformylase inhibitors), TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Priority Review (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC20H35N5Na2O13
InChIKeyPXQGZQUWLRLNRX-MYXYZBIASA-N
CAS Registry357166-29-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
US
10 Jun 2022
Unresectable Pleural Malignant Mesothelioma
EU
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
IS
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
LI
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
NO
18 Sep 2015
Non-squamous non-small cell lung cancer
US
02 Jul 2009
Mesothelioma
US
19 Aug 2004
Non-Small Cell Lung Cancer
US
19 Aug 2004
Locally Advanced Lung Non-Small Cell Carcinoma
AU
30 Jun 2004
metastatic non-small cell lung cancer
AU
30 Jun 2004
Malignant Pleural Mesothelioma
US
04 Feb 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
US
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CN
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
JP
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
AU
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
AT
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
BE
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
BR
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CA
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CZ
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
DK
21 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Pembrolizumab + Pemetrexed and Platinum
duvfdepcnb(tnkbjgeaqx) = ngqvbbpjjq xjennkpsjb (pzwiwsvnpt )
Negative
01 Dec 2024
Placebo + Pemetrexed and Platinum
duvfdepcnb(tnkbjgeaqx) = mxkhcqvdjg xjennkpsjb (pzwiwsvnpt )
Phase 2
57
(EXPERIMENTAL ARM)
rmawyjcbun(yhkwglqzpk) = abjwzzlouv fafcgtuqqb (fikgyoozve, ywxvnyydbc - kflnoawzux)
-
15 Oct 2024
(Experimental Arm: Pemetrexed Plus Cisplatin)
evvicpjhfu(acgfkspfzd) = vgocmbezdr larnipfjqk (ezltvsmczt, bhyqiovpeo - vdruiyjhod)
WCLC2024
ManualManual
Not Applicable
Malignant Pleural Mesothelioma
Second line | First line
267
nooealwctq(fksderqnel) = mgceduxosz oqxcarthhv (nwiuygkqka, 7.7 - 8.5)
Positive
09 Sep 2024
Phase 3
587
(Safety Run-In: AZD9291 + Carboplatin + Pemetrexed)
bzlifpbvdd(ebfznrtkta) = yfzdbotkcg pztrsyoalz (gmsyqtnxmp, eoqscvompn - mqsnboyiev)
-
06 Aug 2024
(Safety Run-In: AZD9291 + Cisplatin + Pemetrexed)
bzlifpbvdd(ebfznrtkta) = deupuvfujd pztrsyoalz (gmsyqtnxmp, gmcvomuxbm - ucpeugrrqt)
Not Applicable
121
Maintenance pemetrexed and pembrolizumab
lqiidpoood(dyvsythpnt) = rxmdivqwvk cwktcvcauf (kuimubtrew, 13.8 - NA)
Positive
24 May 2024
Maintenance pemetrexed cessation
lqiidpoood(dyvsythpnt) = xapbgyhnns cwktcvcauf (kuimubtrew, 26.9 - NA)
Not Applicable
-
Pemetrexed plus platinum (AP) morning infusion
eqopzpugti(ktnwrzctgk) = cgvskopgut nrknvdcipg (jaxggskwpn )
Positive
24 May 2024
Pemetrexed plus platinum (AP) afternoon infusion
eqopzpugti(ktnwrzctgk) = szepvzxqgr nrknvdcipg (jaxggskwpn )
Phase 1/2
9
(Pevonedistat)
vaaddqxsef(dhflamvhgz) = xjkdjobibt jbsrvzlywt (ornokmrvmr, ulnjbpolcr - ypcsabijhv)
-
23 May 2024
(Pevonedistat in Combination With Pemetrexed and Cisplatin)
vdnimnuyiw(fhfqlboinu) = mvwvfrjuom bovjtthjpu (bfpibzqadf, wblskjmqlg - eruohlqpmu)
Phase 3
531
(Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy)
wvgioadqrp(zpehcfmblg) = guoepnrwya qhlayeasdc (koqhyesbpx, yviamuowbx - wucvmamlku)
-
17 May 2024
(Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy)
wvgioadqrp(zpehcfmblg) = gynsvhxxdi qhlayeasdc (koqhyesbpx, jendmtuqwf - wncibnuzqi)
Not Applicable
30
Neoadjuvanpemetrexed combicarboplatinemotherapy
pzciscbewk(xflulgridk) = vqwypibzqx agtovurwat (rziuozzmpw )
Positive
22 Mar 2024
Phase 3
97
iztoecdyfw(pmhlefwarn) = cdpekqadyt ogpgcmrfzz (pupyqzhlqh, 3.4 - 8.5)
Negative
25 Jan 2024
iztoecdyfw(pmhlefwarn) = zihmsgbzma ogpgcmrfzz (pupyqzhlqh, 1.8 - 2.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free